Print
Email
Print Edition StoriesTuesday, February 12, 2008
Mersana Therapeutics taps Lowinger as chief scientific officer
Mersana Therapeutics Inc. has named Timothy B. Lowinger as new chief scientific officer at the Cambridge-based nanotech life sciences company.
Lowinger most recently served as vice president of chemistry and pharmaceutical sciences at Angiotech Pharmaceuticals Inc. of Vancouver, Canada, where he managed a team focused on developing polymer-based pharmaceutical products.
From 1993 to 2007, Lowinger held a number of positions at Bayer Pharmaceuticals in the United States, Germany and Japan. He led the team that discovered and advanced Nexavar, an anti-cancer agent that is approved for indications including renal and hepatocellular cancer, with Phase III studies under way in non small-cell lung and other cancers.
Mersana launched a Phase I trial of its anti-cancer agent XMT-1001 in patients with solid tumors in May 2007.
Privately held Mersana is a venture-backed company, using its proprietary nanotechnology platform to transform existing and experimental anti-cancer agents into new, patentable drugs with better pharmaceutical properties.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
